Vyant Bio Shares Jump On Parkinson's Disease Agreement

• Vyant Bio Inc (NASDAQ:VYNT) and OrganoTherapeutics have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson’s Disease. Specific deal terms were not disclosed.
• The companies will focus on identifying drug candidates that rescue the PD phenotype through developing disease-linked, clinically- translatable assays and biomarkers. 
• The approach will integrate and leverage OrganoTherapeutic’s patient-derived, 3D-organoid disease models derived from induced pluripotent stem cells (iPSCs), Vyant Bio’s iPSC expertise, and its AnalytiX machine learning technology.
• Price Action: VYNT shares are up 36.3% at $1.84 during the premarket session on the last check Wednesday.